hMLH1, hMSH2 and cyclooxygenase-2 (Cox-2) in sporadic colorectal polyps

被引:0
|
作者
Balbinotti, Raul Angelo [1 ]
Ribeiro, Ulysses, Jr. [2 ]
Saka, Paulo [2 ]
Safatle-Ribeiro, Adriana Vaz [2 ]
Balbinotti, Silvana Sartori [1 ]
Scapulatempo, Cristovam [2 ]
Alves, Venancio Avancini Ferreira [3 ]
Corbett, Carlos Eduardo Pereira [2 ,3 ]
机构
[1] Univ Caxias do Sul, Sch Med, Dept Gastroenterol, Caxias Do Sul, RS, Brazil
[2] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil
[3] Univ Sao Paulo, Sch Med, Dept Pathol, BR-05508 Sao Paulo, Brazil
关键词
hMLH1; hMSH2; Cox-2; immunohistochemistry; adenomas; polyps; colorectal cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Colorectal adenomatous polyps are known as premalignant lesions. Mutations in the mismatch repair (MMR) enzymes hMLH1, hMSH2 and hMSH6 are recognized causes of hereditary non-polyposis colorectal cancer and act by inducing a mutator phenotype characterized by microsatellite instability (MSI). MSI is also detected in sporadic colorectal cancers. Cox-2 is an inducible enzyme that regulates prostaglandin synthesis and it is overexpressed at sites of inflammation, in colorectal adenomatous polyps and cancer. The aim of this study was to evaluate the immunoexpression of hMLH1, hMSH2 and Cox-2 in polyps resected through colonoscopy, and to examine their association with clinicopathological characteristics (age, gender, location, size, histology and grade of dysplasia). Patients and Methods: One hundred and sixty-seven colonic polyps, 6 normal colonic mucosa samples, and 23 samples of colorectal adenocarcinoma were used in this study. All patients had no family history of colorectal cancer. The samples were prospectively collected and immunostained for hMLH1 hMSH2 and Cox-2 using the ABC-immunohistochemistry technique with amplification by biotinylated tyramide. The mean age was 60.2 +/- 13.8 years (range 21-90 years) and 77 (55.8%) were men. Results: Tubular adenomas were present in 81.4%, tubulous-villous in 15.9%, serrated in 1.8%, and villous in 0.9%. The majority of the adenomas were located in the rectosigmoid region (63.5%), followed by ascendant in 14.2%, cecum in 7.5%, descendent in 8.2% and transverse in 6.7%. Low-grade dysplasia was detected in 59.6% of the adenomas. Loss of hMLH1 and hMLH2 immunoexpression was observed in 20% and 15.5% of the adenomas, respectively. Cox-2 expression was found in 9% of the adenomas, and in 40% of the adenocarcinomas. Moreover, Cox-2 immunoexpression was associated with the multiplicity of adenomas in the same patient (p=0.001). There was no association between marker immunoexpression and gender, age, location, size, histology or grade of dysplasia. Conclusion: Loss of hMLH1 and hMLH2 immunoexpression in adenomas is relatively frequent in patients without colorectal cancer family history. Cox-2 is overexpressed in colorectal adenomatous polyps and adenocarcinomas, and its positivity in adenomas may indicate a higher risk for multiple lesions.
引用
收藏
页码:4465 / 4471
页数:7
相关论文
共 50 条
  • [31] Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma
    Rosen, Daniel G.
    Cai, Kathy Q.
    Luthra, Rajyalakshmi
    Liu, Jinsong
    MODERN PATHOLOGY, 2006, 19 (11) : 1414 - 1420
  • [32] DNA mismatch repair genes hMLH1, hMSH2, and hMSH6 are not inactivated in bronchioloalveolar carcinomas of the lung
    Aubry, MC
    Halling, KC
    Myers, JL
    Tazelaar, HD
    Yang, P
    Thibodeau, SN
    CANCER, 2001, 92 (11) : 2898 - 2901
  • [33] Expression of cyclooxygenase-2 (COX-2) in colorectal carcinoma in an indigenous African population of Kano, Nigeria
    Abdulrazaq, Jimoh Ajanaku
    Zakari, Mohammed Aminu
    Ibrahim, Yusuf
    Ahmad, Hamza
    ECANCERMEDICALSCIENCE, 2024, 18
  • [34] Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients
    Magdalena, Magnowska
    Pawel, Surowiak
    Ewa, Nowak-Markwitz
    Marcin, Michalak
    Piotr, Magnowski
    Wojciech, Rokita
    Helena, Kedzia
    Maciej, Zabel
    Marek, Spaczynski
    GINEKOLOGIA POLSKA, 2008, 79 (12) : 826 - 834
  • [35] Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy
    Milas, L
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04): : S66 - S69
  • [36] Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma
    Onguru, Onder
    Gamsizkan, Mehmet
    Ulutin, Cuneyt
    Gunhan, Omer
    NEUROPATHOLOGY, 2008, 28 (01) : 29 - 34
  • [37] Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression
    Florence Jourdan
    Nicole Sebbagh
    Eva Comperat
    Najat Mourra
    Antoine Flahault
    Sylviane Olschwang
    Alex Duval
    Richard Hamelin
    Jean-François Flejou
    Virchows Archiv, 2003, 443 : 115 - 121
  • [38] Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression
    Jourdan, F
    Sebbagh, N
    Comperat, E
    Mourra, N
    Flahault, A
    Olschwang, S
    Duval, A
    Hamelin, R
    Flejou, JF
    VIRCHOWS ARCHIV, 2003, 443 (02) : 115 - 121
  • [39] Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer
    Kassem, HS
    Varley, JM
    Hamam, SM
    Margison, GP
    BRITISH JOURNAL OF CANCER, 2001, 84 (03) : 321 - 328
  • [40] Immunohistochemistry for hMLH1 and hMSH2: A practical test for DNA mismatch repair-deficient tumors
    Marcus, VA
    Madlensky, L
    Gryfe, R
    Kim, H
    So, K
    Millar, A
    Temple, LKF
    Hsieh, E
    Hiruki, T
    Narod, S
    Bapat, BV
    Gallinger, S
    Redston, M
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (10) : 1248 - 1255